Methotrexate

Generic Name
Methotrexate
Brand Names
Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
Drug Type
Small Molecule
Chemical Formula
C20H22N8O5
CAS Number
59-05-2
Unique Ingredient Identifier
YL5FZ2Y5U1
Background

Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...

Indication

Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
Associated Therapies
Medically induced abortion
Clinical Trials
Related News

Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL

First Posted Date
2021-05-24
Last Posted Date
2021-05-24
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
42
Registration Number
NCT04899453
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

First Posted Date
2021-05-24
Last Posted Date
2024-12-18
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
42
Registration Number
NCT04898894
Locations
🇺🇸

Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Texas Children's Hospital, Houston, Texas, United States

🇺🇸

Rady Children's Hospital-San Diego, San Diego, California, United States

and more 8 locations

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

First Posted Date
2021-05-05
Last Posted Date
2023-12-20
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
20
Registration Number
NCT04872790
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients

Phase 1
Withdrawn
Conditions
Proliferative Vitreoretinopathy
Interventions
Drug: Methotrexate
First Posted Date
2021-04-05
Last Posted Date
2023-04-20
Lead Sponsor
Stanford University
Registration Number
NCT04830878
Locations
🇺🇸

Byers Eye Institute at Stanford University and Lucille Packard Children Hospital, Palo Alto, California, United States

Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum TWEAK Level in Psoriasis

First Posted Date
2021-03-23
Last Posted Date
2021-03-23
Lead Sponsor
Aswan University Hospital
Target Recruit Count
30
Registration Number
NCT04811911
Locations
🇪🇬

Aswan University - Faculty of Medicine, Aswan, Aswan Governorate, Egypt

Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis

First Posted Date
2021-03-15
Last Posted Date
2023-09-21
Lead Sponsor
Hospital San Carlos, Madrid
Target Recruit Count
192
Registration Number
NCT04798755
Locations
🇪🇸

Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

🇪🇸

Hospital Universitario 12 de Octubre, Madrid, Spain

🇪🇸

Hospital Clínico San Carlos, Madrid, Spain

and more 11 locations

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

First Posted Date
2021-02-12
Last Posted Date
2023-11-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
17
Registration Number
NCT04752163
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

First Posted Date
2021-02-10
Last Posted Date
2024-11-22
Lead Sponsor
University of Chicago
Target Recruit Count
25
Registration Number
NCT04747912
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

First Posted Date
2021-02-04
Last Posted Date
2023-05-18
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
30
Registration Number
NCT04737889
Locations
🇨🇳

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

CHronic Nonbacterial Osteomyelitis International Registry

First Posted Date
2021-01-26
Last Posted Date
2024-07-30
Lead Sponsor
Seattle Children's Hospital
Target Recruit Count
2000
Registration Number
NCT04725422
Locations
🇺🇸

Seattle Children's Hospital, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy